Semaglutide Sublingual

Semaglutide is a GLP-1 receptor agonist approved by the FDA for Type 2 diabetes that acts on brain centers to suppress appetite. Clinical trials demonstrate that participants lost an average of 37 pounds when combining semaglutide with diet changes. At higher doses, it increases insulin secretion and helps patients adhere to a reduced-calorie diet. Sublingual administration bypasses the digestive system, potentially offering improved bioavailability and reduced gastrointestinal side effects like nausea and vomiting, which are typically manageable. This formulation is designed for month 2 or maintenance dosage.